Add like
Add dislike
Add to saved papers

Clinicopathologic factors and adjuvant treatment effects on survival in adult head and neck synovial cell sarcoma.

Head & Neck 2015 March
BACKGROUND: Synovial cell sarcoma is a rare soft tissue sarcoma. The purpose of this study was to investigate clinicopathologic factors and management on survival in primary synovial sarcoma of the head and neck.

METHODS: We conducted a retrospective case series of medical records. Standard Kaplan-Meier survival analyses and accompanying log-rank tests were used.

RESULTS: Twenty-eight patients were identified. All patients had surgery in attempt to remove the primary lesion. Nine patients received adjuvant radiation therapy, 2 received chemotherapy, and 14 received chemoradiation therapy postoperatively. Metastases on initial presentation and tumor size >4 cm decreased survival. No significant effect on overall survival or local tumor recurrence with histologic subtype, lymph node involvement at diagnosis, tumors >5 cm, or when comparing adjuvant therapy types.

CONCLUSION: Although surgery remains the mainstay of treatment, our results do not suggest that adding chemotherapy to postoperative radiotherapy confers a survival or control benefit.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app